FDA approves atovaquone/proguanil combination (NDA 21-078) for the treatment and prophylaxis of Plasmodium faciparum malaria on July 14. Treatment efficacy was found in 98.7% of 521 evaluable patients. In a study of prevention, 2 out of 279 patients receiving Malarone developed malaria over a 10 to 12 week period, compared to 92 of 297 patients receiving placebo, labeling states. Tablets for adults contain 250 mg atovaquone and 100 mg proguanil; pediatric tablets contain 62.5 mg atovaquone and 25 mg proguanil
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth